 | Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. |
|
| The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. Today, there are more than 190 companies plus partners developing more than 430 antibody based oncology drugs in more than 770 developmental projects. In all targeting around 50 different cancer indications. The number of antibody targets has increased to over 170 described molecular targets in just a few years. These targets are further categorized on the CD-ROM by 37 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Antibody in Oncology: Drug Pipeline Update is organized. |
|
| Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years.There are today more than 340 therapeutics targeting breast cancer, from early preclinical to marketed drugs. Breast Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. These targets are further categorized on the CD-ROM by 49 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Breast Cancer Drug Pipeline Update is organized. |
|
| Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.There are today more than 240 apoptopic drugs for the treatment of cancer, from early preclinical to marketed drugs. Apoptosis in Oncology: Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 173 different targets. These targets are further categorized on the CD-ROM by 51 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Apoptosis in Oncology: Drug Pipeline Update is organized. |
|
| Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy will provide the key to market growth. |
|
| Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. There are today more than 390 therapeutics targeting hematological cancers, from early preclinical to marketed drugs. Hematological Cancers Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 197 different targets. These targets are further categorized on the CD-ROM by 50 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Hematological Cancers Drug Pipeline Update is organized. |
|
| Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today more than 240 therapeutics targeting leukemia, from early preclinical to marketed drugs. Leukemia Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 132 different targets. These targets are further categorized on the CD-ROM by 46 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Leukemia Drug Pipeline Update is organized. |
|
| There are today more than 200 anti-angiogenic/vascular disruptive/vascular targeting agents drugs in oncology, from early preclinical to marketed drugs. Angiogenesis in Oncology: Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 138 different targets. These targets are further categorized on the CD-ROM by 38 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Angiogenesis in Oncology: Drug Pipeline Update is organized. |
|
| Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators in oncology drug development into one source.There are today more than 850 immunotherapy drugs in oncology, from early preclinical to marketed drugs. Immunotherapy in Oncology: Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 264 different targets. TThese targets are further categorized on the CD-ROM by 49 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Immunotherapy in Oncology: Drug Pipeline Update is organized. |
|
| Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today more than 180 therapeutics targeting lymphoma, from early preclinical to marketed drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 103 different targets. These targets are further categorized on the CD-ROM by 39 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Lymphoma Drug Pipeline Update is organized. |
|
| Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market wide open.There are today more than 235 cancer vaccines, from early preclinical to marketed drugs. Cancer Vaccines Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 91 different targets. These targets are further categorized on the CD-ROM by 40 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Cancer Vaccines Drug Pipeline Update is organized. |
|
| Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient's remains below 12 months. More than 80,000 new SCLC cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease. |
|
| Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there is plenty of room for more competition. |
|
| Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. |
|
| Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.There are today no less than 190 therapeutics targeting melanoma, from early preclinical to marketed drugs. Melanoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to more than 131 different targets. These targets are further categorized on the CD-ROM by 42 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Melanoma Drug Pipeline Update is organized. |
|
| According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate is 94%.There are today no less than 58 therapeutics targeting bladder cancer, from early preclinical to marketed drugs. Bladder Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 39 different targets. These targets are further categorized on the CD-ROM by 21 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Bladder Cancer Drug Pipeline Update is organized. |
|
| The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets. |
|
| With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for existing and pipeline drugs.There are today more than 200 therapeutics targeting ovarian cancer, from early preclinical to marketed drugs. Ovarian Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 119 different targets. These targets are further categorized on the CD-ROM by 42 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Ovarian Cancer Drug Pipeline Update is organized. |
|
| There are today more than 175 therapeutics targeting pancreatic cancer, from early preclinical to marketed drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 129 different targets. These targets are further categorized on the CD-ROM by 41 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Pancreatic Cancer Drug Pipeline Update is organized. |
|
| There are today more than 90 therapeutics targeting liver cancer, from early preclinical to marketed drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 67 different targets. These targets are further categorized on the CD-ROM by 32 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Liver Cancer Drug Pipeline Update is organized. |
|
